Ozlem Anak MD

Ozlem is Senior Global Clinical Program Head at Novartis for CD19 CAR-T compound Kymriah (Tisagenlecleucel- CTL019). She has been working in oncology development for about 20 years in non-profit academic organizations such as EORTC (European Organization of Research and Treatment of Cancer) and in Pharma industries, Roche and Novartis. Prior to cell and gene arena, she had wide drug development experience in oncology including antibody and small molecule developments in several indications. She is currently leading the clinical development of Kymriah in lymphoma indications. She is based in Basel Switzerland.